Patients with acute coronary syndromes have an increased risk of stent thrombosis. A considerable proportion of these patients are also at increased risk of bleeding, representing a challenge to optimal selection of stent type and duration of dual antiplatelet therapy. Recent evidence supports polymer-free drug-eluting stents as a safe and effective option for this challenging subset of patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tada, T. et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc. Interv. 6, 1267–1274 (2013).
Levine, G. N. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2016.03.513 (2016).
Roffi, M. et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 37, 267–315 (2016).
Steg, P. G. et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 32, 1854–1864 (2011).
Steg, P. G. et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33, 2569–2619 (2012).
Byrne, R. A., Joner, M. & Kastrati, A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur. Heart J. 36, 3320–3331 (2015).
Urban, P. et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N. Engl. J. Med. 373, 2038–2047 (2015).
Mehilli, J. et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113, 273–279 (2006).
Naber, C. K. et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehw203 (2016).
Ndrepepa, G. & Kastrati, A. Minimising bleeding during percutaneous coronary intervention. BMJ 350, h1395 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.K. holds patents related to drug-eluting stent technology. Y.H. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Harada, Y., Kastrati, A. Polymer-free drug-eluting stents — a safe and effective option for ACS. Nat Rev Cardiol 13, 447–448 (2016). https://doi.org/10.1038/nrcardio.2016.110
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2016.110
